(Q42601640)

3 November 2017

title

Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia (English)

1 reference

3 November 2017

1 reference

George M Simpson

1

1 reference

3 November 2017

Cedric J O'Gorman

series ordinal

2

1 reference

3 November 2017

Antony Loebel

series ordinal

3

1 reference

3 November 2017

Ruoyong Yang

series ordinal

4

1 reference

3 November 2017

publication date

1 October 2008

1 reference

3 November 2017

1 reference

3 November 2017

volume

13

1 reference

3 November 2017

issue

10

1 reference

3 November 2017

page(s)

898-905

1 reference

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Switching antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

Effect of initial ziprasidone dose on length of therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Effect of initial ziprasidone dose on treatment persistence in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Mortality and medical comorbidity among patients with serious mental illness.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900017004

7 January 2021

10.1017/S1092852900017004

Identifiers

DOI

1 reference

3 November 2017

1 reference